Mild Cognitive Impairment: Clinical Trials

68 trials for Mild Cognitive Impairment, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

36 completed, 12 unknown, 8 recruiting, 4 active not recruiting. 68 Phase 1, 23 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 168Completed 36, Unknown 12, Recruiting 8, Active not recruiting 4, Terminated 4, Not yet recruiting 2, Withdrawn 2
Phase 223Completed 12, Unknown 5, Recruiting 3, Not yet recruiting 2, Active not recruiting 1

Follow Mild Cognitive Impairment: new trials by email Literature Review of Mild Cognitive Impairment trials Research Report on Mild Cognitive Impairment

Trials (filtered) newest first · largest first

All 68 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
18F-PF974, 18F-florbetaben - Alzheimer s Disease, Mild Cognitive Impairment
Phase 1RecruitingNational Institute of Mental Health (NIMH)902026-11-232026-11-18
2-Hydroxybenzylamine (2-HOBA) Study in Early Alzheimer's Patients
2-hydroxybenzylamine acetate, Placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 1 / Phase 2Not yet recruitingMTI Biotech Inc482026-09-012026-09-24
Sense4Safety Intervention
Sense4Safety - Mild Cognitive Impairment
Phase 1 / Phase 2RecruitingUniversity of Pennsylvania2002026-02-192026-03-19
Epileptic Hippocampus in Alzheimer's Disease
Brivaracetam - Alzheimer Disease, Mild Cognitive Impairment
Phase 1 / Phase 2Not yet recruitingUniversity of California, Los Angeles252026-01-012026-01-27
The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment
Metfomin - Mild Cognitive Impairment, Overweight or Obesity
Phase 1 / Phase 2RecruitingFudan University542025-09-012026-02-09
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
Time-restricted eating - Mild Cognitive Impairment, Alzheimer Disease
Phase 1RecruitingUniversity of California, San Diego602025-04-232026-05-26
Phenserine on the Alzheimer's Treatment Horizon, Study 1
Phenserine, Donepezil (AriceptĀ®) - Alzheimer Disease, Mild Cognitive Impairment
Phase 1CompletedHelse Stavanger HF162025-02-012026-05-04
Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI
Sublingual administration, Electroencephalography, Biochemical mesurements - Mild Cognitive Impairment, Anxiety State
Phase 1 / Phase 2CompletedBiomind Labs Inc.202024-12-152025-04-09
CogT pSOPT Intervention Study
pSOPT, MLA - Mild Cognitive Impairment, Subjective Cognitive Impairment
Phase 1CompletedStanford University502024-01-122026-11-18
Effects Multimodal Mind and Body Approach for MCI
Experimental: A computer-based multimodal mind and body approach (cbMMBA), A standard cognitive training group - Mild Cognitive Impairment
Phase 1CompletedMassachusetts General Hospital322023-12-112026-03-09
rTMS in Older Adults With MCI and AUD
Active, Open Label iTBS-rTMS - Alcohol Use Disorder, Mild Cognitive Impairment
Phase 1Active not recruitingMedical University of South Carolina352023-11-012026-09-17
Protecting Alzheimer Caregivers Using Technology Through Staying Sharp
Staying Sharp intervention - Mild Cognitive Impairment, Dementia Alzheimers
Phase 1 / Phase 2UnknownOregon Health and Science University1382023-04-302023-02-09
Care Partner-Assisted Diabetes Self-Management Through Linking Continuous Glucose Monitoring With Mobile Health: Improving Outcomes for Older Adults With Mild Cognitive Impairment
Continuous Glucose Monitor (CGM) - Type 2 Diabetes, Mild Cognitive Impairment
Phase 1CompletedNYU Langone Health142023-04-192026-08-27
Innate Immunity Stimulation Via TLR9 in Early AD
CpG1018, Placebo - Mild Cognitive Impairment, Alzheimer Dementia
Phase 1RecruitingNYU Langone Health182023-03-132026-01-07
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
NIO752, Matching placebo - Alzheimer Disease, Mild Cognitive Impairment
Phase 1Active not recruitingNovartis Pharmaceuticals382023-02-232026-09-18
Neurodegenerative Alzheimer's Disease and Amyotrophic Lateral Sclerosis (NADALS) Basket Trial
Baricitinib - Amyotrophic Lateral Sclerosis, Alzheimer Disease
Phase 1 / Phase 2CompletedMassachusetts General Hospital172022-12-052026-06-30
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Centella asiatica product, Placebo - Mild Cognitive Impairment, Alzheimer's Disease
Phase 1RecruitingOregon Health and Science University482022-12-012025-04-11
Diminishing Accelerated Long-term Forgetting in Mild Cognitive Impairment
NITESGON, Lidocaine / Prilocaine Topical Cream, C5/C6 stimulation - Mild Cognitive Impairment, Memory Impairment
Phase 1 / Phase 2CompletedUniversity of Dublin, Trinity College802022-09-012026-01-26
ALSENLITE: Senolytics for Alzheimer's Disease
Dasatinib, Quercetin - Mild Cognitive Impairment, Alzheimer Disease
Phase 1 / Phase 2Active not recruitingMayo Clinic202022-07-062026-07-17
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
AAV2-BDNF Gene Therapy - Alzheimer's Disease, Mild Cognitive Impairment
Phase 1Active not recruitingMark Tuszynski122022-02-072026-07-10

Showing 20 of 68. Sign in to see all of them.

Narrower conditions

Cognitive Dysfunction (68)  ·  Alzheimer Disease (36)  ·  Dementia (11)  ·  Parkinson Disease (4)  ·  Brain Diseases (2)  ·  Central Nervous System Diseases (2)  ·  Depression (2)  ·  Inflammation (2)  ·  Memory Disorders (2)  ·  Neurodegenerative Diseases (2)  ·  Tauopathies (2)  ·  Alcoholism (1)  ·  Amyotrophic Lateral Sclerosis (1)  ·  Anxiety Disorders (1)  ·  Autism Spectrum Disorder (1)

Broader conditions

Cognition Disorders (68)  ·  Mental Disorders (68)  ·  Neurocognitive Disorders (67)  ·  Nervous System Diseases (42)  ·  Central Nervous System Diseases (40)  ·  Brain Diseases (39)  ·  Neurodegenerative Diseases (35)  ·  Tauopathies (34)  ·  Dementia (29)  ·  Behavior (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Basal Ganglia Diseases (4)  ·  Movement Disorders (4)  ·  Neurobehavioral Manifestations (4)  ·  Neurologic Manifestations (4)

Interventions

Donepezil (3)  ·  4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (2)  ·  Transcranial Direct Current Stimulation (2)  ·  (11C)-MC1 (1)  ·  1018 oligonucleotide (1)  ·  11C-PS13 (1)  ·  2-(aminomethyl)phenol (1)  ·  7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1)  ·  Administration, Sublingual (1)  ·  Anesthetics, Local (1)  ·  Brain-Computer Interfaces (1)  ·  Dabigatran (1)  ·  Dasatinib (1)  ·  Drug Evaluation (1)  ·  Emtricitabine (1)

Sponsors

Massachusetts General Hospital (3)  ·  Mayo Clinic (3)  ·  Merck Sharp & Dohme LLC (2)  ·  NYU Langone Health (2)  ·  National Institute of Mental Health (NIMH) (2)  ·  Oregon Health and Science University (2)  ·  Seoul National University Bundang Hospital (2)  ·  University of California, Los Angeles (2)  ·  VA Office of Research and Development (2)  ·  AC Immune SA (1)  ·  AbbVie (1)  ·  Actinogen Medical (1)  ·  Adeona Pharmaceuticals (1)  ·  Avid Radiopharmaceuticals (1)  ·  Biomind Labs Inc. (1)

Countries

United States (40)  ·  Canada (4)  ·  Australia (3)  ·  Netherlands (3)  ·  Finland (2)  ·  France (2)  ·  Israel (2)  ·  Singapore (2)  ·  Sweden (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Brazil (1)  ·  China (1)  ·  Ireland (1)  ·  Italy (1)

Top investigators

Alexander C Conley, PhD (1)  ·  Amala Soumyanath, Ph.D (1)  ·  Arjun Masurkar, MD (1)  ·  Barry Halliwell (1)  ·  Benjamin M. Hampstead, PhD (1)  ·  Chao-Yi Wu, PhD (1)  ·  Christopher Chen (1)  ·  Christopher R Martens, Ph.D. (1)  ·  Daniel H. Silverman, MD, Ph.D. (1)  ·  David M Burger, PharmD, PhD (1)  ·  David Newsome, M.D. (1)  ·  David Q Beversdorf, MD (1)

Results publications

PMID 19198615, PMID 19812460, PMID 21358740, PMID 22172392, PMID 22252372, PMID 22409311, PMID 22986776, PMID 23152610, PMID 23300829, PMID 24068826, PMID 24260218, PMID 26302439, PMID 30052328, PMID 31424410, PMID 33344752, PMID 34366147, PMID 34570177, PMID 34670118, PMID 36117569, PMID 36170815, PMID 39422960, PMID 39542698, PMID 39544014, PMID 39760921, PMID 40009460, PMID 40368603, PMID 41225155, PMID 42083927, PMID 42372258, PMID 42382101, PMID 42791030

NIH funding

2018 (2), 1UF1AG046148 (1), 2017 (1), IK2RX002938 (1), K01AG054731 (1), P30AG024978 (1), P50AA010761 (1), P50AG005136 (1), R01AG060981 (1), R01AG090377 (1), R61AG085253 (1)